MICHAEL A WEISS, M.D.
Osteopathic Medicine at Euclid Ave, Cleveland, OH

License number

Ohio 60042

Personal information

See more information about MICHAEL A WEISS at radaris.com

Name

Address

Phone

Michael Weiss

5012 Duke Ave, Cleveland, OH 44102

(216) 410-5780

Michael Weiss, age 102

5279 Lynd Ave, Cleveland, OH 44124

(440) 442-3946

Michael M Weiss

13506 Clifton Blvd, Lakewood, OH 44107

Michael P Weiss, age 48

1764 Brookfield Rd, Hubbard, OH 44425

Michael P Weiss, age 48

1805 Roberts Ln NE, Warren, OH 44483

Organization information

See more information about MICHAEL A WEISS at bizstanding.com

Michael Weiss MD

10900 Euclid Ave, Cleveland, OH 44106

Industry:

Internist

Phone:

(216) 368-5991 (Phone)

Michael Aaron Weiss

Professional information

See more information about MICHAEL A WEISS at trustoria.com

Professor And Chairman, Department Of Biochemistry, School Of Medicine At Case Western Reserve University

Position:

Professor and Chairman, Department of Biochemistry, School of Medicine at Case Western Reserve University, Professor of Biomedical Engineering (Joint Appointment); School of Engineering at Case Western Reserve University, Cowan-Blum Professor of Cancer Research at Case Western Reserve University, President and CSO at Thermalin Diabetes, LLC, Professor of Medicine, Endocrine Division at Case Western Reserve University

Location:

Cleveland/Akron, Ohio Area

Industry:

Higher Education

Work:

Case Western Reserve University since 1999 - Professor and Chairman, Department of Biochemistry, School of Medicine Case Western Reserve University since Jan 2012 - Professor of Biomedical Engineering (Joint Appointment); School of Engineering Case Western Reserve University since 1999 - Cowan-Blum Professor of Cancer Research Thermalin Diabetes, LLC since 2009 - President and CSO Case Western Reserve University since 1999 - Professor of Medicine, Endocrine Division Cleveland Museum of Natural History 2009 - 2013 - Trustee University of Chicago 1994 - 1999 - Professor and Deputy Director (Cancer Center)

Education:

Case Western Reserve University - Weatherhead School of Management 2008 - 2010
MBA, Academic medical center Harvard University 1978 - 1986
Ph.D., Biophysics Harvard Medical School 1978 - 1985
MD Trinity College; Oxford, England 1980 - 1981
Harvard University 1975 - 1978
AB, Physics Wiley Jr High and CWRU

Interests:

Structural mechanisms of human diseases, transcriptional deregulation, and protein misfolding with applications to diabetes and disorders of sexual development.

Honor & Awards:

Elected Member, Beta Gamma Sigma (Business School Honorary Society, 2010) Elected Member, American Association of Physicians (April 2000) Richard Day Distinguished Young Alumnus Award, Hawken School (2000) Dale Cowan and Ruth Goodman Blum Chair, Case Western Reserve University (1999) Fletcher Scholars Award in Cancer Research, Cancer Research Foundation (1997-1999) Lucille Markey Scholar, The University of Chicago (1994-1998) Bane Scholar, The University of Chicago (1994-1998) Established Investigator of the American Heart Association (July 1994-1998) Elected Member, American Society for Clinical Investigation (April 1992) Pfizer Scholars Program for New Faculty (1989-1992) American Cancer Society Junior Faculty Research Award (1989-1992) American Diabetes Association Research Development Award (1988-1991) Juvenile Diabetes Foundation Career Development Award (1989-1992) Harvard Medical School Soma Weiss Research Award (1985) Sheldon Traveling Fellow, Harvard University (1980-1981)

Awards:

Maurice Saltzman Award
Mt. Sinai Health Care Foundation

Certifications:

Licensed Physician in State of Ohio (Oct. 2005-present)
Licensed Physician in State of Illinois (July 1996-present)
Licensed Physician in Commonwealth of Massachusetts (July 1988-present)

Michael Aaron Weiss, Cleveland OH

Specialties:

Internal Medicine, Endocrinology, Diabetes & Metabolism

Work:

Case Western Reserve University
10900 Euclid Ave, Cleveland, OH 44106

Education:

Harvard University(1985)

Long-Acting Insulin Analogue Preparations In Soluble And Crystalline Forms

US Patent:

2013008, Apr 4, 2013

Filed:

Feb 22, 2011

Appl. No.:

13/580656

Inventors:

Michael Weiss - Moreland Hills OH, US

Assignee:

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH

International Classification:

A61K 38/28

US Classification:

514 62, 536 2351, 4353201, 43525233, 43525421, 43525423

Abstract:

A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin A-chain sequence that contains paired Histidine substitutions at A4 and A8, and optionally a substitution at A21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules. The formulation forms a long-acting zinc-dependent subcutaneous depot upon subcutaneous injection. In a zinc-free formulation, the insulin analogue monomer exhibits decreased affinity for the Insulin-like Growth Factor receptor and at least 20% of the affinity for the insulin receptor of the same species, in comparison to an otherwise identical insulin or insulin analogue that does not contain the Hisand Hissubstitutions.

Fibrillation Resistant Proteins

US Patent:

8343914, Jan 1, 2013

Filed:

Jan 8, 2007

Appl. No.:

12/160187

Inventors:

Michael Weiss - Moreland Hills OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 38/28, C07K 14/62, C12N 15/00

US Classification:

514 62, 514 63, 514 64, 530303, 530304, 435 691

Abstract:

Protection of proteins against fibrillation may be afforded by introduction of certain histidine substitutions into the protein, such that a pair of histidines are present with sufficient spacing as to allow the histidines to coordinate with zinc. In the case of insulin, introduction of histidine residue substitutions at residues A4 and A8 together or a histidine residue substitution at residue B1, provides increased resistance to fibrillation while maintaining at least a majority of the activity of the insulin analogue. Introduction of a histidine residue substitution at residue A8 restores at least a portion of fibrillation resistance that may have been harmed by substitutions present on the B-chain such as those present in fast-acting insulins. Proteins protected by such histidine substitutions may be used to provide a pharmaceutical composition. A method of treating a patient includes administering a physiologically effective amount of the pharmaceutical composition to the patient.

Halogen-Stabilized Insulin

US Patent:

2011016, Jul 7, 2011

Filed:

Jan 31, 2011

Appl. No.:

13/018011

Inventors:

Michael WEISS - Moreland Hills OH, US

Assignee:

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH

International Classification:

A61K 38/28, C07K 14/62, C07H 21/04, C12N 15/63, A61P 3/10, C12N 1/00

US Classification:

514 63, 530303, 536 2351, 4353201, 435243

Abstract:

An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.

Fibrillation-Resistant Insulin And Insulin Analogues

US Patent:

8192957, Jun 5, 2012

Filed:

Apr 6, 2009

Appl. No.:

12/419169

Inventors:

Michael Weiss - Moreland Hills OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 38/28, C07K 14/62, C12N 15/17, C12N 15/63, C12N 1/21

US Classification:

435 697, 435 691, 435 711, 4353201, 530303, 514 62, 514 63

Abstract:

A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays less than 1 percent fibrillation with incubation at 37° C. for at least 21 days. A single-chain insulin analogue displays greater in vitro insulin receptor binding than normal insulin while displaying less than or equal binding to IGFR than normal insulin. The fibrillation-resistant insulin may be used to treat a patient using an implantable or external insulin pump, due to its greater fibrillation resistance.

Isoform-Specific Insulin Analogues

US Patent:

2011019, Aug 11, 2011

Filed:

Apr 22, 2009

Appl. No.:

12/989399

Inventors:

Michael Weiss - Moreland Hills OH, US
Jonathan Whittaker - Shaker Heights OH, US

Assignee:

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH

International Classification:

A61K 38/28, C07K 14/62, C12N 15/17, C12N 15/63, C12N 5/00, A61P 3/10

US Classification:

514 59, 530303, 536 2351, 4353201, 435325

Abstract:

A method treating a mammal by administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof where the insulin analogue displays more than twofold greater binding affinity to insulin receptor isoform A (IR-A) than insulin receptor isoform B (IR-B). The insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A-chain sequence or an analogue thereof and an insulin B-chain sequence or an analogue thereof connected by a polypeptide of 4-13 amino acids. A single-chain insulin analogue may display greater in vitro insulin receptor binding to IR-A but lower binding to IR-B than normal insulin while displaying less than or equal binding to IGFR than normal insulin.

Non-Standard Insulin Analogues

US Patent:

8399407, Mar 19, 2013

Filed:

Sep 17, 2010

Appl. No.:

12/884943

Inventors:

Michael A. Weiss - Moreland Hills OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 38/28, A61P 3/10, C07K 14/62

US Classification:

514 59, 514 69

Abstract:

An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide. A first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate. The methylated phenylalanine may be ortho-monofluoro-phenylalanine, meta-monobromo-phenylalanine or para-monochloro-phenylalanine. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.